SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Name
Hemann_SYK is.pdf
Size
3.32 MB
Format
Adobe PDF
Checksum (MD5)
0e65252c5ddac79f5aa5554181bdd706
Author(s)
Puissant, Alexandre
Alexe, Gabriela
Pikman, Yana
Bassil, Christopher F.
Mehta, Swapnil
Du, Jinyan
Kazi, Julhash U.
Luciano, Frédéric
Rönnstrand, Lars
Kung, Andrew L.
Date Issued
February 2014
Journal
Cancer Cell
Publisher
Elsevier
Citation
Puissant, Alexandre, Nina Fenouille, Gabriela Alexe, Yana Pikman, Christopher F. Bassil, Swapnil Mehta, Jinyan Du, et al. “SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia.” Cancer Cell 25, no. 2 (February 2014): 226–242.
Version
Author's final manuscript
Abstract
Cooperative dependencies between mutant oncoproteins and wild-type proteins are critical in cancer pathogenesis and therapy resistance. Although spleen tyrosine kinase (SYK) has been implicated in hematologic malignancies, it is rarely mutated. We used kinase activity profiling to identify collaborators of SYK in acute myeloid leukemia (AML) and determined that FMS-like tyrosine kinase 3 (FLT3) is transactivated by SYK via direct binding. Highly activated SYK is predominantly found in FLT3-ITD positive AML and cooperates with FLT3-ITD to activate MYC transcriptional programs. FLT3-ITD AML cells are more vulnerable to SYK suppression than FLT3 wild-type counterparts. In a FLT3-ITD in vivo model, SYK is indispensable for myeloproliferative disease (MPD) development, and SYK overexpression promotes overt transformation to AML and resistance to FLT3-ITD-targeted therapy.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.ccr.2014.01.022
